ArticleJournal of assisted reproduction and genetics2026
Distinct metabolomic profiles in lean and non-lean polyendocrine metabolic ovarian syndrome.
Article in Journal of assisted reproduction and genetics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposePolycystic ovary syndrome (PCOS)/polyendocrine metabolic ovarian syndrome (PMOS) is the most prevalent endocrine disorder in reproductive-age women and is characterized by long-term metabolic consequences. The purpose of this study is to delineate the metabolomic profile in lean and non-lean PMOS patients.
methodsRetrospective cross-sectional study includes 4768 premenopausal patients with available body mass index (BMI) and metabolomics information at the Mass General Brigham (MGB) Biobank. The Biobank includes samples collected from 05/2010 to 08/2023 with unique metabolomic biomarkers that encompass key metabolic pathways, including lipids, amino acids, and glycolysis-related metabolites. The main outcome measures were metabolomic profile differences between PMOS (n = 403) and non-PMOS patients (n = 4365). Sub-analyses were performed within normal BMI (< 25 kg/m
resultsPMOS patients were younger (p < 0.001) and had higher BMI (p < 0.001). When considering the total population and adjusting for age, BMI, exercise, metformin, oral contraceptive pills (OCPs), and glucagon like peptide-1 (GLP-1) agonists, PMOS affected the expression of only 1/71 (1.4%) parameter compared to the non-PMOS group. In the normal BMI sub-group, there were no differences in any of the metabolomic parameters when controlling for age, exercise, metformin, OCPs, and GLP-1 agonists except for creatinine levels that were lower in PCOS. In the overweight BMI sub-group, when adjusting for the same confounders, PMOS diagnosis had an impact on 4/71 (5.6%) of the metabolomic parameters, mostly in the family of amino acids. Lastly, in the obesity BMI subgroup, adjusted analysis showed no association between PMOS and any of the metabolites under evaluation.
conclusionMetabolomic signatures of PMOS differ by BMI phenotype. Minimal disturbances were noted in lean PMOS patients. In contrast, PMOS patients with overweight BMI demonstrate broader metabolomic differences and subsequent implications.
Indexed as
Identifiers
42658451What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.